Impact Biomedical Inc.
IBO· NYSE
Released Aug 13, 2024, after the close
10-Q filed Aug 13, 2024, 44 days after period end · 0001493152-24-031635
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|
| Revenue | — | — | $50.00K |
| Net Income | -$889.00K | -$1.12M | -$799.00K |
| EPS Diluted | -$0.09 | -$0.02 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Impact Biomedical Inc. · CIK 1834105 · Engraved from SEC EDGAR